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During endochondral ossification, type I collagen is synthesized by osteoblasts together with some hypertrophic chondrocytes. Type I collagen
has also been reported to be progressively synthesized in degenerative joints. Because Matrix Metalloproteinase-13 (MMP-13) plays an active role
in remodeling cartilage in fetal development and osteoarthritic cartilage, we investigated whether type I collagen could activate MMP-13
expression in chondrocytes. We used a well-established chondrocytic cell line (MC615) and we found that MMP-13 expression was induced in
MC615 cells cultured in type I collagen gel. We also found that a1h1 integrin, a major collagen receptor, was expressed by MC615 cells and we
further assessed the role of a1h1 integrin in conducting MMP-13 expression. Induction of MMP-13 expression by collagen was potently and
synergistically inhibited by blocking antibodies against a1 and h1 integrin subunits, indicating that a1h1 integrin mediates the MMP-13-inducing
cellular signal generated by three-dimensional type I collagen. We also determined that activities of tyrosine kinase and ERK and JNK MAP
kinases were required for this collagen-induced MMP-13 expression. Interestingly, bone morphogenetic protein (BMP)-2 opposed this induction,
an effect that may be related to a role of BMP-2 in the maintenance of cartilage matrix.
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The matrix metalloproteinases (MMPs) are a family of zinc-
dependent endopeptidases that play multiple roles in biology of
the extracellular matrix (ECM), such as release of cryptic
fragments and neo-epitopes from ECM macromolecules,
release of growth factors and modification of cell–ECM
interface [1]. Because MMPs degrade most components of
the ECM, they have been particularly studied in the context of
ECM remodeling. For instance, during endochondral ossifica-
tion, MMPs are associated with chondrocyte hypertrophy [2,3]
and with matrix vesicles implicated in cartilage mineralization
[4–7]. More precisely, proteolysis involving MMP-13 (colla-
genase-3) is required for hypertrophic chondrocyte differenti-
ation in vitro [3,8], and this is consistent with reports that0167-4889/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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of mammalian growth plate [9–15]. MMP-13 is also expressed
by early osteogenic cells of the bone collar and by osteoblasts
invading the growth plate [16]. These findings together suggest
that MMP-13 plays an active role in remodeling cartilage and
bone during long bone development. Accordingly, biochemical
characterization of this enzyme has revealed that it degrades
very efficiently fibrillar collagens such as type II collagen,
major protein in cartilage, and type I collagen, major protein in
bone [17]. MMP-13 can also degrade type X collagen [18] and
aggrecan [19], two other cartilage macromolecules.
In addition to its role in skeletal development, MMP-13 is
involved in cartilage pathology. MMP-13 is expressed in adult
articular cartilage in human osteoarthritis (OA) [20] and
experimental OA [21–23], and a direct correlation between
excess production of MMP-13 and cartilage destruction has
been demonstrated by the cleavage of type II collagen in
human OA [20].ta 1746 (2005) 55 – 64
http://www
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molecular signaling pathways that regulate MMP-13 expres-
sion in chondrocytes have been only partially identified. The
120-kDa fibronectin fragment (FN-f) stimulates production of
MMP-13 by human chondrocytes through the a5h1 integrin
receptor and activation of ERK, JNK, and p38 mitogen-
activated protein (MAP) kinases [24]. Recently, it has been
shown that this FN-f-induced signaling involves activation of
protein kinase C (PKC) [25]. In addition, MAP kinase
activation has been linked to MMP-13 expression in response
to interleukin-1h in chondrocytes [26–28] in response to TGF-
h1 in breast cancer cells [29], transformed keratinocytes [30]
and fibroblasts [31,32] and in response to fibroblast culture in
collagen gels [33].
Type II collagen is the major protein of cartilage but a
switch occurs from type II collagen to type I collagen at sites
where MMP-13 is involved in cartilage degradation, like in
hypertophic cartilage [34,35]. Furthermore, the presence of
type I collagen has also been reported in osteoarthritic cartilage
[36–39]. In this context, we investigated whether type I
collagen signals chondrocytes to activate MAP kinase pathway
and subsequent expression of MMP-13. We used the well-
established chondrocytic cell line (MC615) that has been
shown to express several biochemical markers of the articular
cartilage [40–44]. We first found that three-dimensional (3-d)
collagen gel promotes MMP-13 expression in MC615 cells.
We also found that a1h1 integrin, a major collagen receptor
expressed at the surface of chondrocytes [45], is expressed in
MC615 cells, and we further showed that this integrin mediates
3-d collagen signaling responsible for MMP-13 expression. We
determined that activities of tyrosine kinase and ERK and JNK
MAP kinases were required for this collagen-induced MMP-13
expression. These results demonstrate for the first time that
type I collagen via a1h1 integrin and MAPK signaling can
mediate MMP-13 expression in chondrocytes. Lastly, we
showed that BMP-2 opposes this collagen induction of
MMP-13 expression. This interesting finding raises the
possibility that type I collagen and BMP-2 signaling act in
balance in cartilage homeostasis, suggesting a chondroprotec-
tive capacity for BMP-2.
2. Materials and methods
2.1. Cell culture
The MC615 cell line was characterized previously [40] and routinely
maintained in 1:1 high-glucose DMEM/Ham’s F12 containing 10% FBS and
supplemented with 2 mM l-glutamine, 100 U/ml penicillin, 100 Ag/ml
streptomycin (all products from GIBCO-Invitrogen, Cergy-Pontoise, France).
2.2. Type I collagen gels
Collagen was extracted and purified as described [46] from the skin of
young calves (kindly provided by Symate`se Biomate´riaux Lyon, France). Four
volumes of this collagen in 7 mM acetic acid solution, characterized as
containing 98% type I collagen and 2% type III collagen, were mixed with one
volume of 5 concentrated DMEM/Ham’s F12 supplemented with 200 U/ml
penicillin and 200 Ag/ml streptomycin for a final concentration of 1.25 mg/ml,
neutralized with 0.5 M NaOH and kept on ice. MC615 cells were trypsinized,
resuspended in DMEM/Ham’s F12 supplemented with 100 U/ml penicillin and100 Ag/ml streptomycin, and mixed with neutralized collagen solution to a final
concentration of 2106 cells/ml. One milliliter of this mixture was transferred
into each well of a 24-well plate and incubated at 37 -C in the presence of 5%
CO2 for collagen polymerization. After 1 h, 1 ml DMEM/Ham’s F12
containing 1% FBS and supplemented with 2 mM l-glutamine, 100 U/ml
penicillin and 100 Ag/ml streptomycin was added in each well, and the
incubations continued for different periods of time. Alternatively, MC615 cells
were embedded in agarose gel as previously described [41], and with the same
seeding conditions as in collagen gel. The culture medium was replaced each
day. In experiments involving BMP-2, tyrosine kinase or MAPK inhibitors, or
blocking antibodies against different collagen-binding integrin subunits, these
were added to the cell suspension prior to mixing it with neutralized collagen
solution. These modulators were replaced with the culture medium each day. In
experiments involving two-dimensional (2-d) cell cultures, MC615 cells were
plated on Corning dishes or Biocoat type I collagen-coated dishes (BD
BioSciences, Le Pont de Claix, France) and cultured in the same medium as the
cells embedded in collagen gel.
2.3. Reagents and antibodies
Recombinant human BMP-2 was a gift of Wyeth Research (Cambridge,
MA, USA). Recombinant human MMP-13 was obtained from R and D
Systems (Lille, France) and goat polyclonal anti-mouse MMP-13 antibodies
were a kind gift from C. Peeters-Joris and were previously described [47].
Monoclonal Hamster antibodies raised against mouse integrin h1 chain
(CD29), rat/mouse integrin a1 chain (CD49a), rat integrin a2 chain
(CD49b), and Hamster IgG were obtained from BD Pharmingen (Le Pont de
Claix, France). The CD29, CD49a and CD49b antibodies have been shown to
recognize the respective integrin subunits by flow cytometry [48]. Antibodies
anti-PYK2 were from Upstate Biotechnology (Charlottesville, VA, USA) and
anti-phospho-PYK2 (Y402) were from Cell Signaling (Beverly, MA, USA).
The tyrosine kinase inhibitor Genistein, the MEK inhibitor PD 98059 and the
p38 inhibitor SB 203580 were obtained from Calbiochem (San Diego, CA,
USA). The JNK inhibitor SP 600125 was purchased from Sigma-Aldrich
(L’Isle d’Abeau, France). Preliminary experiments indicated that BMP-2 and
inhibitors have no effect on multiplication of MC615 cells cultured for 4 days
in collagen gel (data not shown).
2.4. Flow cytometry
MC615 cells were released from collagen gels by a 15 min treatment with
1.5 mg/ml collagenase (type IA, Sigma) in phosphate-buffered saline (pH 7.4)
with 1 mM CaCl2. For integrin detection, cells were washed and resuspended in
PBS containing saturating amounts of mAbs against integrins. After 20-min
incubation at 4 -C, cells were washed and resuspended in PBS containing
FITC-mouse anti-hamster IgG (BD Pharmingen). Controls were carried out
using isotype-matched antibodies or by omission of primary antibody. Cells
were analysed with a FACS Caliburi cytofluorometer.
2.5. Reverse transcription-polymerase chain reaction (RT-PCR)
MC615 cells were released from collagen gels by a brief treatment with
collagenase, as described above. Total RNA was isolated from cells with the
RNeasy kit (Qiagen, Courtaboeuf, France), and digested with DNase to remove
any contaminating genomic DNA. For RT, a 40 Al reaction contained 1 Ag total
RNA, 12.5 ng/Al oligo(dT12VN) primers (V represents A, G, or C and N
represents A, T, G or C), 500 AM each dNTP, 100 ng/Al BSA, 10 mM DTT, 4 U
of RNasin (Promega, Charbonnie`res les Bains, France) and 200 U SuperScript
II RNase H (GIBCO-Invitrogen). Reactions were carried out at 42 -C for 50
min followed by an inactivation of the enzyme at 70 -C for 15 min. The cDNAs
were then incubated with 4 U RNase H (GIBCO-Invitrogen) at 37 -C for 30
min. For PCR amplification, a 50 Al reaction contained 2 Al RT aliquot, 50 AM
each dNTP, 0.2 AM each primer, 1.5 mM MgCl2 and 2.5 U AmpliTaq DNA
polymerase (Applied Biosystems, Villebon sur Yvette, France). Following an
initial denaturation step of 2 min at 95 -C, amplification consisted of 30–35
cycles of 30 s at 95 -C, 30 s at optimal temperature (see Table 1), and 30 s at 72
-C, followed by a final extension step of 5 min at 72 -C. Amplification was
performed in a GeneAmp PCR system 2400 (Perkin-Elmer, Courtaboeuf,
Table 1
Oligonucleotide primers used for the PCR analyses
Gene Primers Strand Product
size (bp)
T (-C) PCR cycles Source
MMP-13 CTGAGCGCTGCGGTTCACTT + 501 53 35 X66473
ACGCAAGAATCAGGTGATCC 
a1 integrin subunit AGCCTCTTGCCTCTTACTTG + 603 55 30 BC014765
AACTTCAGCGTCTTGCCATC 
a2 integrin subunit GACTGCAGAACCACTTCCTG + 474 57 35 NM_008396
AGTCCATTCACCACACCAGC 
h1 integrin subunit CACAGCAGCAGCATCTTAGT + 535 55 30 Y00769
AGATTTCCTTCCCACCTCTC 
GAPDH ATCACTGCCACCCAGAAGAC + 443 57 25 M32599
ATGAGGTCCACCACCCTGTT 
Primers are presented in a 5V to 3V orientation, with that for the coding strand (+) being above that for the non coding strand (). The product size generated by
reverse transcription and PCR amplification of the mRNA is indicated, together with the annealing temperature and the number of PCR cycles used for each primer
set. The source of the databank used for designing the primers is presented as an accession number.
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banks (see Table 1). The RT-PCR products were separated by electrophoresis
on 1.5% agarose gels and stained with ethidium bromide. In initial
experiments, RT-PCR products were cloned in a pCR2.1-TOPO vector
(Invitrogen) and sequenced (Genome Express, Meylan, France) to confirm the
identity of the sequences. No PCR product was observed when the reverse
transcriptase was omitted during the synthesis of cDNA, or when RT reaction
volume was replaced with water in the PCR reaction (data not shown).
Message for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used
to ascertain that an equivalent amount of cDNA was synthesized from the
different samples, as reported previously [43]. Photographs of gels of RT-PCR
experiments were analyzed with Image Quant software (Amersham Bios-
ciences, Orsay, France).
2.6. Analysis of MMP-13 production
MC615 cells were grown in different culture conditions, as indicated. After
1, 4 and 7 days, equal aliquots of 24 h conditioned media were analyzed by
zymography or Western blotting. For gelatin-substrate zymography, 30 Al
samples were mixed with 4 Laemmli’s non reducing loading buffer and
subjected to electrophoresis in 10% polyacrylamide gels containing 0.1%
gelatin. When indicated, zymographies were carried out under reducing
conditions by addition of 40 mM DTT in the 4 loading buffer, to inhibit
gelatinases, MMP-2 and MMP-9 [47]. After electrophoresis, gels were washed
three times with 50 mM Tris–HCl buffer (pH 7.5) containing 100 mM NaCl
and 2.5% Triton X100 then incubated at 37 -C for 16 h in 50 mM Tris–HCl
(pH 7.5) containing 100 mM NaCl, 10 mM CaCl2. Gels were stained with 0.5%
Coomassie brilliant blue R-250 and destained.
For Western blotting analysis, 45 Al samples were subjected to SDS-
polyacrylamide gel electrophoresis. The proteins were electrotransferred to
nitrocellulose membranes (Millipore, Molsheim, France), immunoblotted with
anti-mouse MMP-13 antibody followed by horseradish peroxidase-labeled
secondary antibodies and visualized using the Covalight chemiluminescent
detection system (Covalab, Lyon, France).
2.7. Western immunoblot analysis
For PYK2 analysis, MC615 cells embedded in collagen gels were
transferred in mini-columns (Handee Spin Columns, Pierce, Lausanne, Suisse),
centrifuged 10 s to remove the medium and rinsed twice with PBS containing
40 Ag/ml soybean trypsin inhibitor, 2 mM NaF and 2 mM Na3VO4. Cell lysates
were prepared using modified cold cell lysis RIPA buffer: 50 mM Tris (pH 7.4),
150 mM NaCl, 1% Nonidet P-40, 0.25% deoxycholate, 2 mM NaF, 2 mM
Na3VO4, 5 mM EDTA, 2 Ag/ml aprotinin, 2 Ag/ml leupeptin, 5 Ag/ml pepstatin,
10 mM N-ethylmaleimide, 40 Ag/ml soybean trypsin inhibitor and 1 mM
phenylmethylsulfonyl fluoride and stored at 20 -C. After centrifugation for 15
min at 12000g, extracts were separated by SDS-polyacrylamide gels
electrophoresis (PAGE) and proteins were visualized by Coomassie blue
staining to load equal amounts of proteins for immunoblots. Immunoblottingwas performed using polyvinylidene fluoride membranes and a chemilumines-
cent detection system (Immun-Star, Biorad, Marnes la Coquette, France).
3. Results
3.1. 3-d type I collagen induces MMP-13 expression in MC615
chondrocytes
To explore the role of type I collagen in promoting MMP-13
expression in chondrocytes, we cultured MC615 cells for 1 and
4 days in type I collagen gel and determined MMP-13 protein
production by gelatin zymography of culture medium, and
MMP-13 gene expression by RT-PCR. MMP-13 protein and
RNA expression was clearly detected at day 1 and this
expression increased noticeably at day 4 (Fig. 1A). Concom-
itantly, robust and similar levels of expression of MMP-2
protein were observed at day 1 and day 4 (Fig. 2A). Next, we
further demonstrated by Western blotting analysis that induc-
tion of MMP-13 protein expression occurs when MC615 cells
are cultured in 3-d type I collagen gel and not when cultured on
type I collagen monolayer-coated surface, nor on plastic (Fig.
2B). Similarly, no MMP-13 gene expression was detected by
RT-PCR in MC615 cells cultured for 1 or 4 days on type I
collagen monolayer-coated surface, or on plastic (data not
shown). The chondrocytic cell line MC615 is maintained in a
proliferative state by immortalization with the large T oncogene
of the simian virus 40 [40]. Therefore, MMP-13 expression in
collagen gel could result from an alteration of the chondrocytic
phenotype provoked by a 3-d environment that may impair cell
proliferation. To exclude this possibility, MMP-13 expression
was also assessed with MC615 cells cultured in 3-d agarose
gel. We previously demonstrated that the doubling time of
MC615 cells is in fact considerably slower in agarose gel that
in monolayer [41]. Nevertheless, our Western blotting analysis
did not reveal any MMP-13 protein in the medium collected
from agarose culture (Fig. 2B). Taken together, these results
indicate that propagation of MC615 cells in a 3-d matrix is not
itself sufficient to upregulate MMP-13 production, since cells
cultured in 3-d agarose did not demonstrate elevated MMP-13
expression. Thus, induction of MMP-13 is specific to a 3-d
collagen matrix.
Fig. 1. Three-dimensional (3-d) type I collagen induces MMP-13 expression in
MC615 cells. (A) Top, Gelatin zymography using culture media of MC615
cells. MC615 cells were grown within type I collagen gel or on plastic in the
presence of DMEM/HamF12 with 1% FBS, for 1 or 4 days, as indicated. For
the two culture conditions, the medium shows the presence of proMMP-2 (the
upper band and lower band represent the glycosylated and non-glycosylated
form, respectively). The proMMP-13 and MMP-13 are detected in conditioned
medium of MC615 cells cultured in 3-d collagen gel only. Note: MMP-13 can
appear as a doublet by gelatin zymography. Recombinant human MMP-13
(Rec.) was used as a control. Bottom, RT-PCR analysis of mRNA expression of
MMP-13 in MC615 cells grown within type I collagen gel as in (A), and on
plastic. (B) The level of proMMP-13 was determined by Western blotting
analysis using a specific antibody. MC615 cells were cultured in two-
dimensional (2-d) conditions on plastic or type I collagen-coated dish, and in
3-d conditions in type I collagen or agarose gel, for 1 or 4 days, as indicated.
Fig. 2. MC615 cells express a1 and h1 integrin subunits, but not a2 integrin
subunit. (A) After 1 h of culture in type I collagen gel, MC615 cells were
assayed by flow cytometry for the expression of a1, a2 and h1 integrin
subunits at the cell surface. The filled histograms represent background
fluorescence obtained with secondary antibody only and the open histograms
represent specific fluorescence obtained with monoclonal anti-integrin subuni
antibodies. (B) RT-PCR analysis of expression of a1, a2 and h1 integrin
subunits in MC615 cells cultured as in (A). PCR amplification generates
product size of 603 bp, 474 bp and 535 bp for a1, a2 and h1 integrin subunit
respectively. The 100-bp DNA ladder is shown on the left.
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by 3-d type I collagen is mediated via a1b1 integrin
Up-regulation of MMP-13 expression in fibroblasts cultured
in type I collagen gel has been shown to be mediated by a1h1
and a2h1 integrins [33], two collagen receptors also found to
be expressed on the surface of isolated chondrocytes [45].
Therefore, we looked for a potential role of these integrins in
the type I collagen-dependent induction of MMP-13 expression
in chondrocytes. First, the expression of a1, a2 and h1 integrin
subunits was analyzed by flow cytometry and RT-PCR when
MC615 cells were cultured for 1 h in collagen gel. MC615
cells clearly expressed a1 and h1 integrin subunits but noa2 integrin subunit (Fig. 2A and B). Identical profiles of
expression for a1, a2 and h1 subunits were obtained by flow
cytometry and RT-PCR when MC615 cells were routinely
cultured on plastic and for 4 days in type I collagen gel,
indicating that collagen did not modify the expression of these
integrin subunits (data not shown). These findings suggested
that a1h1 integrin could play a role in the collagen-dependent
induction of MMP-13 expression in MC615 cells. To test this
hypothesis, we studied the effect of blocking antibodies against
a1 and/or h1 integrin subunits to MC615 chondrocytes before
embedding them in type I collagen gels. The cells exhibited a
spherical morphology immediately after their embedding in
collagen gel (data not shown). Following their embedding,
MC615 cells gradually developed an elongated morphology in
the controls (Fig. 3A). Addition of antibodies against a1 and/or
h1 integrin subunits inhibited this shape change and, after 1
day, MC615 cells showed a more round-up morphology in
presence of both antibodies than in presence of each one (Fig.
3A). Analysis at the mRNA and protein levels revealed that
antibodies against a1 and/or h1 integrin subunits inhibited
MMP-13 gene and protein expression (Fig. 3B and C). More
precisely, this inhibition appeared to be stronger at the protein
level in presence of both antibodies (Fig. 3C). Together, these
observations indicate that the induction of MMP-13 expression
in MC615 chondrocytes by 3-d type I collagen involves
activation of signaling via a1h1 integrin.
3.3. Induction of MMP-13 expression in MC615 chondrocytes
cultured in type I collagen gel is dependent on tyrosine kinase
activity
Focal adhesion kinase (FAK) and proline-rich tyrosine
kinase-2 (PYK2) are closely related tyrosine kinases that can
mediate integrin signaling and subsequent MAP kinaset
,
Fig. 3. Induction of MMP-13 expression by MC615 chondrocytes in type I
collagen gel is mediated by a1h1 integrin. (A) Morphology of MC615 cells
cultured in collagen gel for 1 day and photographed under a phase-contrast
microscope. Prior to seeding in collagen gel, hamster IgG (IgG: 5 Ag/ml), or
blocking antibodies against a1 (anti-a1, CD49a : 5 Ag/ml), and/or h1 (anti-h1,
CD29 : 5 Ag/ml) integrin subunits were added to cell suspension, as indicated.
MC615, no antibodies added. (B) Top, RT-PCR analysis of MMP-13 gene
expression in MC615 cells cultured in collagen gel for 1 day. Prior to seeding in
collagen gel, hamster IgG or blocking antibodies against a1 and/or h1 integrin
subunits were added to cell suspension, under the conditions described in (A).
Bottom, densitometric quantitation of the MMP-13 mRNA levels. The values
are shown relative to GAPDH mRNA levels and are arithmetic means with the
error bars representing standard deviations of three independent experiments.
(C) Gelatin zymography using culture media of MC615 cells grown for 4 days
in collagen gel. Cells were treated with hamster IgG, anti-a1 and/or anti-h1
integrin antibodies, as indicated, under the conditions described in (A).
Fig. 4. Embedding in type I collagen gel triggers phosphorylation of PYK2 in
MC615 chondrocytes. Cell lysates were prepared before (0) or after embedding
in collagen gel, at the indicated time points, then immunoblotted with
phosphospecific (phospho) and non-phosphospecific (total) antibodies to
PYK2.
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to regulate MMP-13 expression in human chondrocytes after
activation by FN-f-induced integrin signaling [25]. When
MC615 chondrocytes were cultured in type I collagen gel, a
rapid increase in phosphorylation of PYK2 at the autopho-
sphorylation site (Y402) was observed and phosphorylationreturned to base line by 22 h (Fig. 4). In parallel, FAK
activation was not significantly detected, as judged by using an
antibody recognizing FAK phosphorylated at the autopho-
sphorylation site (Y397), (data not shown). Next, we added
genistein, a tyrosine kinase inhibitor, to MC615 cells before
embedding them in collagen gel. MMP-2 level was not affected
by treatment with this inhibitor, as shown by our zymography
analysis under non-reducing conditions (Fig. 5A). When 40
mM DTT was added to the loading buffer, the MMP-2 signals
disappeared thus allowing for enhanced visualization of MMP-
13 activity (Fig. 5A). This specific effect of DTT on MMP-2,
but not on MMP-13, is due to the existence of disulfide bridges
in the cysteine-rich fibronectin-like domains which are
exclusively present in gelatinase molecules and are responsible
for their binding to gelatin [47]. As seen under reducing
conditions, induction of MMP-13 protein expression within
collagen gel was inhibited in a dose-dependent manner by
genistein, indicating requirement of tyrosine kinase activity for
collagen-dependent MMP-13 expression (Fig. 5A). MMP-13
induction was also altered by addition of tyrphostin A9 (AG-
17), another tyrosine kinase inhibitor that has been reported to
selectively block the PYK2 signaling pathway in neutrophils
[54] (Fig. 5B). These observations together suggest that PYK2
is part of the type I collagen signaling responsible for MMP-13
expression.
3.4. Type I collagen-dependent induction of MMP-13
expression in MC615 chondrocytes requires ERK and
JNK activity
Next, we used MAP kinase inhibitors to determine whether
MAP kinase activity was involved in mediating the collagen-
dependent induction of MMP-13 in MC615 cells. To block the
ERK1,2 pathway, we added PD 98059, a specific inhibitor of
the activation of MEK1 and MEK2 [55,56]. This inhibitor
dose-dependently inhibited collagen-stimulated MMP-13 (Fig.
6A). In parallel, preincubation of JNK inhibitor SP 600125
[57] provoked the same effect (Fig. 6B). In contrast, addition of
p38 inhibitor SB 203580 [58,59] weakly augmented the
induction of MMP-13, as compared with untreated cells in
collagen gels (Fig. 6A). These results show that the activity of
ERK1,2 and JNK is essential for MMP-13 expression in
collagen-embedded MC615 chondrocytes, whereas the p38
pathway plays an inhibitory role in MMP-13 expression. In
comparison, our zymography analysis under non-reducing
conditions showed that the abundance of MMP-2 protein was
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6A, B), indicating specific effect of the inhibitors on MMP-13
expression and differential regulation of MMP-13 and MMP-2
expression by MAP kinases.
3.5. BMP-2 inhibits type I collagen-dependent induction of
MMP-13 expression in MC615 chondrocytes
We previously reported that BMP-2 stimulates the chon-
drocytic phenotype of MC615 cells cultured on plastic [43,44].
Here, we further investigated the effect of BMP-2 on MC615Fig. 6. Induction of MMP-13 production by MC615 chondrocytes in type
collagen gel is dependent on ERK and JNK activities and is inhibited by p38
MAPK activity. (A) Gelatin zymographies using culture media of MC615 cells
grown for 4 days in collagen gel, in the presence of different concentrations o
PD 98059, a specific inhibitor of ERK1,2 kinases MEK1,2, or SB 203580, a
selective inhibitor of p38 MAPK, or DMSO vehicle alone. Zymographies were
carried out in the presence or absence of DTT, as indicated. MMP-13
production is dose-dependently decreased by PD 98059 and stimulated by SB
203580. (B) Gelatin zymographies using culture media of MC615 cells grown
for 4 days in collagen gel, in the presence of different concentrations of SP
600125, a specific inhibitor of JNK, or DMSO vehicle alone. Zymographies
were carried out in the presence or absence of DTT, as indicated. MMP-13
production is decreased by SP 600125, in a dose-dependent manner.
Fig. 5. Induction of MMP-13 production by MC615 chondrocytes in type I
collagen gel is dependent on tyrosine kinase activity. (A) Left panel, Gelatin
zymographies using culture media of MC615 cells grown for 4 days in collagen
gel, in the presence of different concentrations of tyrosine kinase inhibitor
genistein, or DMSO vehicle alone. Zymographies were carried out in the
presence or absence of DTT, as indicated. MMP-13 production is decreased
dose-dependently by genistein. Right panel, gelatin zymography using culture
media of MC615 cells grown for 7 days in collagen gel in the presence of 25
AM genistein or DMSO vehicle alone. Electrophoresis of the DTT-treated
samples clearly confirms the inhibitory effect of genistein on MMP-13
production. (B) Gelatin zymographies using culture media of MC615 cells
grown for 4 days in collagen gel, in the presence of different concentrations of
tyrosine kinase inhibitor tyrphostin A9, or DMSO vehicle alone. Zymographies
were carried out in the presence or absence of DTT, as indicated. MMP-13
production is decreased dose-dependently by tyrphostin A9.I
fcells cultured in type I collagen gel. Interestingly, a marked
decrease in MMP-13 synthesis was observed when cells were
cultured in the presence of BMP-2, as revealed by zymography
and confirmed by Western blotting analysis (Fig. 7A). This
inhibitory effect of BMP-2 on MMP-13 expression was clearly
observed at the protein level at day 4, and was observed at the
gene level as early as day 1 (Fig. 7B). In parallel, MMP-2
synthesis remained unaffected by treatment with BMP-2 (Fig.
7A), indicating specific effect of BMP-2 on collagen-induced
MMP-13 expression.
4. Discussion
The breakdown of cartilage matrix not only occurs in
osteoarthritic joints but is also necessary for the remodeling of
hypertrophic cartilage into bone during endochondral ossifica-
Fig. 7. BMP-2 inhibits MMP-13 expression induced by type I collagen gel. (A)
Top, gelatin zymography using culture media of MC615 cells grown in
collagen gel for 1 or 4 days in the presence of 1% FBS (0), or of 1% FBS with
25, 50 or 100 ng/ml BMP-2 as indicated. Bottom, the level of proMMP-13 was
determined by Western blotting analysis using a specific antibody on the same
samples as shown on the top. (B) RT-PCR analysis of MMP-13 gene expression
in MC615 cells cultured in collagen gel for 1 day in the presence of 1% FBS
(0), or of 1% FBS with 25, 50 or 100 ng/ml BMP-2, as indicated.
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mediated by matrix metalloproteinases and, among them,
MMP-13 assumes a crucial role. It is known that collagen
matrices comprise specific signals that can either stabilize or
destabilize the phenotype of chondrocytes. For instance,
cartilage fibrils containing type II collagen contribute to the
maintenance of the differentiated cartilage phenotype whereas
contacts with fibrils containing type I collagen destabilize the
phenotype of chondrocytes [60]. In this regard, we analyzed
the role of type I collagen in the regulation of MMP-13
expression in chondrocytes by using a model consisting of
mouse chondrocytes embedded in a type I collagen matrix.
Here, we first show that the expression of MMP-13 in
mouse chondrocytes can be specifically induced by 3-d type I
collagen via a1h1 integrin. In the MC615 cell line, expression
of a1 is unlikely due to the immortalization with SV40 large T
antigen but rather due to the source of the cells. In fact,
immortalization with SV40 large T antigen has allowed the
establishment of chondrocyte cell lines showing great differ-
ences in the level of a1 subunit expression, including no
expression at all [61]. In addition, the expression of a1h1
integrin by MC615 chondrocytes is consistent with the
observation that a1h1, but not a2h1, is expressed on mouse
chondrocytes, as revealed by immunohistochemistry [62] and
flow cytometry [63].
The results of the present study also indicate that induction
of MMP-13 expression by MC615 chondrocytes was depen-
dent on the presence of 3-d type I collagen matrix. The nature
of precise primary signals triggered by a 3-d collagen matrix
remains to be determined but our results are in agreement witha previous report showing that MMP-13 expression in
fibroblasts is specifically induced by 3-d type I collagen [33].
Our results also show that type I collagen-dependent induction
of MMP-13 expression is not completely prevented by addition
of antibodies against a1 and h1 integrin subunits. This may
relate to the efficiency of antibodies or may suggest that other
collagen receptors are involved in this regulation. Receptor
candidates could include a10h1 integrin that is expressed in
chondrocytes [62] Surprisingly, mouse chondrocytes deficient
in a10 integrin subunit do not show reduction in adhesion to
type I and type II collagen, when compared to the wild type
[63]. In fact, the absence of the other collagen-binding integrins
a2h1 and a11h1 together with the presence of a1h1 integrin
both in the a10-deficient and wild-type chondrocytes [63]
suggests indeed that a1h1 plays an important role in collagen-
chondrocyte interactions. Besides, other non-integrin candidate
receptors could include discoidin domain receptor 2 (DDR2)
that has been recently demonstrated to mediate expression of
MMP-13 in mice developing OA [64].
Our results also demonstrate that type I collagen-induced
MMP-13 expression in MC615 chondrocytes is dependent on
tyrosine kinase activity and is linked to activation of MAP
kinase signaling. Precisely, our data strongly suggest that
PYK2, not FAK, is involved in this pathway. Similar to our
findings, a recent study has shown that PYK2, not FAK,
regulates MMP-13 expression in human chondrocytes after
activation by FN-f-induced integrin signaling [65]. In fact,
differential signaling by FAK and PYK2 has been reported in
other cell systems despite the similarities in the two proteins
[66]. Although we did not demonstrate a direct coupling of
PYK2 to activation of MAP kinases in the present study, MAP
kinase activation has been shown to be downstream of the
PYK2 signaling pathway in other cell types [49–53,67]. Our
study has revealed that ERK1,2 and JNK pathways are
involved in collagen-induced MMP-13 expression whereas
blocking the p38 MAPK pathway potently augments this
expression. This situation differs from fibroblasts embedded in
type I collagen gel, where MMP-13 has been shown to be
induced by collagen through p38 activity whereas the activity
of ERK1,2 opposes this induction [33]. In addition, in this last
study, both a1h1 and a2h1 integrins have been found to
mediate collagen signaling responsible for MMP-13 expression
[33] whereas our results indicate that a1h1, but not a2h1, is
involved in collagen-induced MMP-13 expression in chondro-
cytes. Taken together, these data indicate that different type I
collagen signaling pathways exist leading in MMP-13 expres-
sion in fibroblasts and chondrocytes.
The phenotypic regulation of chondrocytes is not only
controlled by the ECM, but also by growth factors, hormones
and cytokines. Previous reports have shown that BMPs are able
to inhibit MMP-13 expression in chondrocytes and osteoblasts
cultured on plastic [68–70]. Very recently, it has been shown
that BMP-2 mediates the suppression of MMP-13 promoter
activity through a Runx2 binding site in osteoblasts [71]. Here,
we found that BMP-2 opposes type I collagen induction of
MMP-13 expression in MC615 chondrocytes and it is
conceivable that BMP-2 also suppresses MMP-13 promoter
M.-C. Ronzie`re et al. / Biochimica et Biophysica Acta 1746 (2005) 55–6462activity in chondrocytes. Besides, the inhibitory effect of BMP-
2 on MMP-13 expression observed in MC615 cells cultured in
type I collagen gel could be the result of a cross-talk between
BMP-2 and type I collagen signaling pathways. Candidate
molecules as crossing points include MAP kinases and Smad
proteins that are important signaling molecules in chondrocytes
[72].
Thus, this study shows for the first time that type I collagen
via a1h1 integrin and MAPK signaling induces MMP-13
expression in chondrocytes. The finding that BMP-2 opposes
this induction is particularly interesting because it could reveal
a critical activity of BMP-2 in maintaining the integrity of the
cartilage matrix. Accordingly, a recent study has revealed that
conditional inactivation of BMP receptor signaling in joint
structures in mice leads to the loss of expression of key
cartilage markers after birth, implying that BMP signaling is
required for postnatal maintenance of articular cartilage [73]. In
conclusion, our results support the view where the phenotypic
flexibility of chondrocytes is tightly controlled by signals of
both the ECM and diffusing factors. In addition, elucidation
of the molecular mechanisms regulating the phenotype of
chondrocytes embedded in collagen gel is also important in the
context of cartilage engineering. Indeed, chondrocytes embed-
ded in type I collagen gel are considered as a therapeutic
approach to repair articular cartilage defects [74,75]. Therefore,
such studies should contribute to determine how to better
control the chondrocyte phenotype embedded in gel, before
transplantation.
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